Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 7, 2021 | Post-IPO Equity | $200M | 14 | — | — | Detail |
Oct 7, 2021 | IPO | $235M | — | — | — | Detail |
Aug 20, 2020 | Series Unknown | $40M | 10 | Lux Capital , Pharmaceutical Product Development , Redmile Group | — | Detail |
Jan 3, 2019 | Series D | $35M | 6 | Pharmaceutical Product Development | — | Detail |
Apr 25, 2017 | Series C | $35M | 7 | Glynn Capital Management | — | Detail |
Oct 18, 2016 | Series B | $31M | 5 | Redmile Group | — | Detail |
Oct 20, 2015 | Series A | $6.50M | 3 | dRx Capital , Lux Capital | — | Detail |